Results 31 to 40 of about 4,832 (178)

Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report

Respiratory Medicine Case Reports, 2020
Eosinophilic chronic rhinosinusitis (ECRS) is characterized by the presence of nasal polyps, dominant ethmoid shadows in computed tomography (CT) scans, and elevated levels of eosinophil infiltration into the nasal polyps and peripheral blood.
Hiroki Kagoshima, Ryusuke Hori, Tsuyoshi Kojima, Yusuke Okanoue, Atsushi Taguchi, Hirotaka Yamamoto, Koki Hasebe, Kazuhiko Shoji   +7 more
doaj   +1 more source

Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics

ERJ Open Research, 2023
Background Benralizumab is highly effective in many, but not all, patients with severe asthma. Baseline characteristics alone are insufficient to predict an individual's probability of long-term benralizumab response.
Johannes A. Kroes, Kim de Jong, Simone Hashimoto, Sander W. Zielhuis, Eric N. van Roon, Jacob K. Sont, Anneke ten Brinke   +6 more
doaj   +1 more source

Anaphylaxis to three humanized antibodies for severe asthma: a case study

Allergy, Asthma & Clinical Immunology, 2020
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi   +9 more
doaj   +1 more source

Benralizumab for eosinophilic granulomatosis with polyangiitis

, 2023
International audienceBackground: Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases.
Pierre Chauvin, Charlene Desaintjean, Mikael Ebbo, Maxime Samson, Vincent Cottin, Pugnet, Grégory, Matthieu Groh, Adrien Cottu, Loïc Guillevin, Lazaro, Estibaliz, Yildiz, Halil, Cécile-Audrey Durel, Halil Yildiz, Desaintjean, Charlene, Grégory Pugnet, Sylvain Marchand-Adam, Elizabeth Diot, Nabil Belfeki, Xavier Puechal, Stephane Jouneau, Diot, Elizabeth, Terrier, Benjamin, Taille, Camille, Jouneau, Stephane, Benjamin Terrier, Groh, Matthieu, Nicolas, Sarah, Marchand-Adam, Sylvain, Durel, Cécile-Audrey, Cathebras, Pascal, Francois Lifermann, Clairelyne Dupin, Cottu, Adrien, Belfeki, Nabil, Guilleminault, Laurent, Lifermann, Francois, Laurent Guilleminault, Sarah Nicolas, Pascal Cathebras, Cottin, Vincent, Ebbo, Mikael, Camille Taille, Chauvin, Pierre, Puechal, Xavier, French Vasculitis Study Group, Dupin, Clairelyne, Stacy Beaumesnil, Guillevin, Loïc, Estibaliz Lazaro, Samson, Maxime, Martellosio, Jean-Philippe, Jean-Philippe Martellosio, Beaumesnil, Stacy   +52 more
core   +1 more source

A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan

, 2016
BACKGROUND: Airway eosinophils are considered to play an important role in the pathogenesis of asthma. Interleukin-5 is believed to be a key cytokine for the development, proliferation and activation of eosinophils.
Imai, N, Park, HS, Ohta, K, Asian Benralizumab Study Group, Kim, MK, Tohda, Y, Adachi, M, Nakanishi, T   +7 more
core   +1 more source

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis

Respirology Case Reports, 2023
There is limited data on the use of benralizumab in patients with severe asthma, who have allergic bronchopulmonary aspergillosis (ABPA). We report the case of a 65‐year‐old woman with combined severe eosinophilic and allergic asthma, who presented with ...
Arvindran Alaga, Khairil Ashraff, Nurul Hana Din Khan   +2 more
doaj   +1 more source

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort

Arthritis &Rheumatology, EarlyView.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis characterized by eosinophilia, asthma, and ear, nose, and throat (ENT) involvement. Although glucocorticoids (GCs) are effective in controlling symptoms, relapses and GC dependence are common. The aim of this study was to develop predictive models for vasculitis
Matthias Papo, Pauline Martinot, Renato A. Sinico, Vítor Silvestre‐Teixeira, Nils Venhoff, Maria‐Letizia Urban, Michele Iudici, Juliane Mahrhold, Francesco Locatelli, Giulia Cassone, Franco Schiavon, Benjamin Seeliger, Thomas Neumann, Claudia Feder, Matthieu Groh, Chiara Marvisi, Maxime Samson, Thomas Barba, David Jayne, Arianna Troilo, Jens Thiel, Bernhard Hellmich, Sara Monti, Carlomaurizio Montecucco, Carlo Salvarani, Jean‐Emmanuel Kahn, Bernard Bonnotte, Cécile‐Audrey Durel, Xavier Puéchal, Luc Mouthon, Loïc Guillevin, Giacomo Emmi, Augusto Vaglio, Raphaël Porcher, Benjamin Terrier, on behalf of the French Vasculitis Study Group and the Eosinophilic Granulomatosis with Polyangiitis European Study Group   +35 more
wiley   +1 more source

Real-life cost-effectiveness of benralizumab in patients with severe asthma

Respiratory Research, 2021
Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems.
A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon   +10 more
doaj   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

, 2019
Severe refractory asthma is characterized by a higher risk of asthma-related symptoms, morbidities, and exacerbations. This disease also determines much greater healthcare costs and deterioration in health-related quality of life (HR-QoL).
Nicola Facciolongo, Francesco Menzella, Mirella Biava, Diego Bagnasco, Patrizia Ruggiero, Anna Simonazzi, Carla Galeone   +6 more
core   +1 more source